Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.62 -1.8%	$1.55	$1.03 ▼ $8.64	$50.54M	-0.27	505,032 shs	404,015 shs
PYRGF PyroGenesis Canada	$0.33 +0.5%	$0.34	$0.30 ▼ $0.80	$62.22M	0.89	11,041 shs	9,752 shs
TTPH Tetraphase Pharmaceuticals	$2.20	$2.20	$0.56 ▼ $8.60	$15.98M	2.33	932,542 shs	282,689 shs
VHAQ Viveon Health Acquisition	$11.00	$11.00	$0.00 ▼ $12.48	$62.26M	-0.1	12 shs	99 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	-1.82%	+10.96%	-1.82%	-10.50%	-78.02%
PYRGF PyroGenesis Canada	+0.45%	-4.28%	-0.21%	-7.42%	-35.28%
TTPH Tetraphase Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
VHAQ Viveon Health Acquisition	0.00%	0.00%	0.00%	0.00%	+10.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATNM Actinium Pharmaceuticals	1.1818 of 5 stars	3.4	2.0	0.0	0.0	0.0	0.0	0.6
PYRGF PyroGenesis Canada	0.1314 of 5 stars	0.0	2.0	0.0	0.0	0.6	1.7	0.0
TTPH Tetraphase Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	2.75	Moderate Buy	$4.00	146.91% Upside
PYRGF PyroGenesis Canada	0.00	N/A	N/A	N/A
TTPH Tetraphase Pharmaceuticals	0.00	N/A	N/A	N/A
VHAQ Viveon Health Acquisition	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TTPH, VHAQ, PYRGF, and ATNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
5/12/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/28/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/1/2025	ATNM Actinium Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	$81K	623.92	N/A	N/A	$1.31 per share	1.24
PYRGF PyroGenesis Canada	$9.14M	6.81	N/A	N/A	($0.01) per share	-33.33
TTPH Tetraphase Pharmaceuticals	$7.38M	2.17	N/A	N/A	$6.68 per share	0.33
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	-$1.39	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
PYRGF PyroGenesis Canada	-$21.12M	-$0.02	N/A	∞	N/A	-115.14%	N/A	-60.81%	N/A
TTPH Tetraphase Pharmaceuticals	-$70.08M	-$22.85	N/A	N/A	N/A	-798.18%	-210.86%	-121.73%	N/A
VHAQ Viveon Health Acquisition	-$610K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PYRGF PyroGenesis Canada	N/A	N/A	N/A	N/A	N/A
TTPH Tetraphase Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VHAQ Viveon Health Acquisition	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
PYRGF PyroGenesis Canada	N/A	0.60	0.50
TTPH Tetraphase Pharmaceuticals	0.06	3.66	3.56
VHAQ Viveon Health Acquisition	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
PYRGF PyroGenesis Canada	0.03%
TTPH Tetraphase Pharmaceuticals	42.29%
VHAQ Viveon Health Acquisition	22.14%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	6.00%
PYRGF PyroGenesis Canada	47.68%
TTPH Tetraphase Pharmaceuticals	5.70%
VHAQ Viveon Health Acquisition	75.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	30	31.20 million	29.32 million	Optionable
PYRGF PyroGenesis Canada	90	186.69 million	96.34 million	No Data
TTPH Tetraphase Pharmaceuticals	119	7.26 million	N/A	Optionable
VHAQ Viveon Health Acquisition	2	5.66 million	1.40 million	Not Optionable

TTPH, VHAQ, PYRGF, and ATNM Headlines

Recent News About These Companies

Viveon Health Acquisition Corp

November 21, 2024 | investing.com

Clearday, Inc. (CLRD)

September 6, 2024 | finance.yahoo.com

Clearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success - Updated

May 3, 2024 | finance.yahoo.com

Clearday Announces Board Resignation of Jeff Coleman with Warm Wishes for His Future Success

May 2, 2024 | finance.yahoo.com

Viveon Health Acquisition Corp.: Viveon Healthcare Acquisition Corp. Confirms Commitment To Proceed With Business Combination Process

February 28, 2024 | finanznachrichten.de

VIVEON HEALTHCARE ACQUISITION CORP. CONFIRMS COMMITMENT TO PROCEED WITH BUSINESS COMBINATION PROCESS

February 27, 2024 | globenewswire.com

NYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)

February 21, 2024 | finance.yahoo.com

Viveon Health Acquisition Corp. Receives Commencement of Delisting Notice From the NYSE

December 27, 2023 | finance.yahoo.com

NYSE American to Commence Delisting Proceedings Against Viveon Health Acquisition Corp. (VHAQ)

December 22, 2023 | tmcnet.com

San Antonio, Texas Clearday (CLRD-OTCQX) is proud to honor our US Veterans through the Company’s Clearday Club in San Antonio, Texas.

November 13, 2023 | finance.yahoo.com

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Viveon Health Acquisition Corp. (VHAQ.WS)

October 24, 2023 | finance.yahoo.com

VHAQ-R Viveon Health Acquisition Corp.

September 23, 2023 | seekingalpha.com

Viveon Health Acquisition Received Audit Opinion With Going Concern Explanation

September 15, 2023 | marketwatch.com

VIVEON HEALTH ACQUISITION CORP. RECEIVED AUDIT OPINION WITH GOING CONCERN EXPLANATION

September 15, 2023 | finance.yahoo.com

Viveon Healthcare Increases Consideration Offered to Clearday Shareholders

September 5, 2023 | finance.yahoo.com

SPAC Viveon ups merger consideration for Clearday to $500M

August 29, 2023 | msn.com

Viveon Health Acquisition Corp. and Clearday, Inc. Announce Amendment to their Definitive Merger Agreement

August 29, 2023 | finance.yahoo.com

VIVEON HEALTH ACQUISITION CORP. RECEIVES NYSE NOTICE REGARDING DELAYED FORM 10-K FILING

April 25, 2023 | finance.yahoo.com

Viveon Health Acquisition Corp. (VHAQ-RT)

April 18, 2023 | finance.yahoo.com

(Updated) Clearday Inc. and Viveon Health Acquisition Corp. Announce Definitive Merger Agreement to Accelerate Innovative Longevity-Tech Platform to Market

April 12, 2023 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTPH, VHAQ, PYRGF, and ATNM Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.62 -0.03 (-1.82%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.62 0.00 (0.00%)

As of 04:05 AM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

PyroGenesis Canada NASDAQ:PYRGF

$0.33 +0.00 (+0.45%)

As of 06/26/2025 03:45 PM Eastern

PyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.

Tetraphase Pharmaceuticals NASDAQ:TTPH

Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.

Viveon Health Acquisition NYSE:VHAQ

$11.00 0.00 (0.00%)

As of 01/30/2025

Viveon Health Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses in the healthcare industry in North America. The company was incorporated in 2020 and is based in Atlanta, Georgia. Viveon Health Acquisition Corp. operates as a subsidiary of Viveon Health LLC.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time